PARTNER-2试验:经导管与外科主动脉瓣生物瓣的结构性 deterioration 比较
本研究基于PARTNER 2A试验和SAPIEN 3注册研究,采用基于超声随访的标准化定义,比较中危重度主动脉瓣狭窄患者接受TAVR或SAVR后5年结构性瓣膜 deterioration(SVD)的发生率。结果显示,SAPIEN XT TAVR的5年SVD发生率显著高于SAVR,而SAPIEN 3 TAVR与SAVR无显著差异。
要点
- SAPIEN XT TAVR的5年SVD发生率显著高于SAVR。
- SAPIEN 3 TAVR的5年SVD发生率与SAVR无显著差异。
- SAPIEN 3的5年SVD发生率显著低于SAPIEN XT。
核心结论
- 与SAVR相比,第二代SAPIEN XT球囊扩张瓣膜5年SVD发生率更高,而第三代SAPIEN 3的SVD发生率与SAVR无差异。
研究设计与样本
- PARTNER 2A试验将中危重度主动脉瓣狭窄患者随机分配至SAPIEN XT TAVR或SAVR,SAPIEN 3注册研究中患者接受SAPIEN 3 TAVR。
- 主要终点为5年SVD发生率,即超声随访期间SVD相关血流动力学瓣膜 deterioration 和/或SVD相关生物瓣膜失败(BVF)的复合终点。
主要发现
- 与SAVR相比,SAPIEN XT TAVR队列的5年暴露调整发生率(每100患者年)显著更高:SVD为1.61 ± 0.24% vs. 0.63 ± 0.16%,SVD相关BVF为0.58 ± 0.14% vs. 0.12 ± 0.07%,全因BVF为0.81 ± 0.16% vs. 0.27 ± 0.10%(所有p ≤ 0.01)。
- SAPIEN 3 TAVR与倾向评分匹配的SAVR队列相比,5年SVD发生率(0.68 ± 0.18% vs. 0.60 ± 0.17%;p = 0.71)、SVD相关BVF(0.29 ± 0.12% vs. 0.14 ± 0.08%;p = 0.25)和全因BVF(0.60 ± 0.15% vs. 0.32 ± 0.11%;p = 0.32)均无显著差异。
- 在匹配队列中,SAPIEN 3 TAVR的5年SVD和SVD相关BVF发生率显著低于SAPIEN XT TAVR。
临床怎么用
- 对于中危重度主动脉瓣狭窄患者,选择TAVR时应考虑瓣膜类型对长期SVD风险的影响。
- SAPIEN 3 TAVR的5年SVD发生率与SAVR相当,支持其在该人群中的中长期应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unknown whether transcatheter valves will have similar durability as surgical bioprosthetic valves. Definitions of structural valve deterioration (SVD), based on valve related reintervention or death, underestimate the incidence of SVD. OBJECTIVES: This study sought to determine and compare the 5-year incidence of SVD, using new standardized definitions based on echocardiographic follow-up of valve function, in intermediate-risk patients with severe aortic stenosis given transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) in the PARTNER (Placement of Aortic Transcatheter Valves) 2A trial and registry. METHODS: In the PARTNER 2A trial, patients were randomly assigned to receive either TAVR with the SAPIEN XT or SAVR, whereas in the SAPIEN 3 registry, patients were assigned to TAVR with the SAPIEN 3. The primary endpoint was the incidence of SVD, that is, the composite of SVD-related hemodynamic valve deterioration during echocardiographic follow-up and/or SVD-related bioprosthetic valve failure (BVF) at 5 years. RESULTS: Compared with SAVR, the SAPIEN-XT TAVR cohort had a significantly higher 5-year exposure adjusted incidence rates (per 100 patient-years) of SVD (1.61 ± 0.24% vs. 0.63 ± 0.16%), SVD-related BVF (0.58 ± 0.14% vs. 0.12 ± 0.07%), and all-cause (structural or nonstructural) BVF (0.81 ± 0.16% vs. 0.27 ± 0.10%) (p ≤ 0.01 for all). The 5-year rates of SVD (0.68 ± 0.18% vs. 0.60 ± 0.17%; p = 0.71), SVD-related BVF (0.29 ± 0.12% vs. 0.14 ± 0.08%; p = 0.25), and all-cause BVF (0.60 ± 0.15% vs. 0.32 ± 0.11%; p = 0.32) in SAPIEN 3 TAVR were not significantly different to a propensity score matched SAVR cohort. The 5-year rates of SVD and SVD-related BVF were significantly lower in SAPIEN 3 versus SAPIEN XT TAVR matched cohorts. CONCLUSIONS: Compared with SAVR, the second-generation SAPIEN XT balloon-expandable valve has a higher 5-year rate of SVD, whereas the third-generation SAPIEN 3 has a rate of SVD that was not different from SAVR. (The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII A [PARTNERII A]; NCT01314313; The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - PARTNERII - S3 Intermediate [PARTNERII S3i]; NCT03222128).
引用
- Pibarot P, Ternacle J, Jaber WA, et al. Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial. J Am Coll Cardiol. 2020. PMID: 33059828. doi:10.1016/j.jacc.2020.08.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。